27494908|t|Management of skin and soft-tissue infections at a community teaching hospital using a severity-of-illness tool
27494908|a|Skin and soft-tissue infections (SSTIs) encompass a diverse range of infections of varying severity. The Clinical Resource Efficiency Support Team (CREST) scoring system stratifies patients into four classes (I = least severe to IV = most severe) based on the Standardized Early Warning Score (SEWS). The objective of this study was to apply CREST to hospitalized patients with SSTIs in order to quantify disease severity and evaluate appropriateness of antibiotic management. This was a retrospective, hypothesis -generating, single-centre evaluation of hospitalized patients with SSTIs admitted in 2011. Based on CREST classification, the empirical antimicrobial choices were categorized as appropriate, over-treatment or under-treatment. A total of 369 patients were screened and 200 met the inclusion criteria. The majority of patients were classified as either CREST class I (n = 68) or class I I (n = 102). Over-treatment was more common in the less severe classes (88% and 32% in class I and class II, respectively; P < 0.05). Sixty-three percent of class I (n = 43) were over-treated due to both the use of intravenous antibiotic s when oral therapy was sufficient and use of unnecessarily broad-spectrum antibiotics. In contrast, 25% (n = 26) of class II were over-treated due to use of unnecessarily broad-spectrum antibiotics. Overall clinical failure rates remained low with only 1%, 4% and 17% of patients unable to achieve initial response in class II, class III and class IV. Retrospective application of CREST identified opportunities to improve the management of SSTIs. CREST can be of great value in discriminating less- severe SSTIs, which can be treated on an outpatient basis.
27494908	0	10	Management	T058	C0376636
27494908	14	45	skin and soft-tissue infections	T047	C0852000
27494908	61	78	teaching hospital	T073,T093	C0020027
27494908	87	111	severity-of-illness tool	T169	C0449851
27494908	112	143	Skin and soft-tissue infections	T047	C0852000
27494908	145	150	SSTIs	T047	C0852000
27494908	164	171	diverse	T080	C1880371
27494908	172	177	range	T081	C1514721
27494908	181	191	infections	T046	C3714514
27494908	203	211	severity	T080	C0439793
27494908	217	281	Clinical Resource Efficiency Support Team (CREST) scoring system	T170	C0162791
27494908	282	292	stratifies	T185	C0008902
27494908	293	301	patients	T101	C0030705
27494908	312	319	classes	T185	C0008902
27494908	331	337	severe	T080	C0205082
27494908	351	357	severe	T080	C0205082
27494908	372	404	Standardized Early Warning Score	T170	C2919819
27494908	406	410	SEWS	T170	C2919819
27494908	417	426	objective	T078	C2985627
27494908	435	440	study	T062	C2603343
27494908	454	459	CREST	T170	C0162791
27494908	463	484	hospitalized patients	T101	C0870668
27494908	490	495	SSTIs	T047	C0852000
27494908	517	533	disease severity	T080	C0521117
27494908	538	546	evaluate	T058	C0220825
27494908	566	576	antibiotic	T195	C0003232
27494908	600	613	retrospective	T062	C0035363
27494908	615	625	hypothesis	T078	C1512571
27494908	653	663	evaluation	T058	C0220825
27494908	667	688	hospitalized patients	T101	C0870668
27494908	694	699	SSTIs	T047	C0852000
27494908	700	708	admitted	T058	C0184666
27494908	727	732	CREST	T170	C0162791
27494908	753	762	empirical	T080	C1880496
27494908	763	776	antimicrobial	T121	C1136254
27494908	790	801	categorized	T052	C0871968
27494908	818	832	over-treatment	T058	C4046039
27494908	836	851	under-treatment	T061	C0087111
27494908	868	876	patients	T101	C0030705
27494908	907	925	inclusion criteria	T080	C1512693
27494908	943	951	patients	T101	C0030705
27494908	957	967	classified	T185	C0008902
27494908	978	983	CREST	T170	C0162791
27494908	984	991	class I	T185	C1550329
27494908	1004	1011	class I	T185	C1550329
27494908	1025	1039	Over-treatment	T058	C4046039
27494908	1068	1074	severe	T080	C0205082
27494908	1075	1082	classes	T185	C0008902
27494908	1099	1106	class I	T185	C1550329
27494908	1111	1119	class II	T185	C1550329
27494908	1158	1165	percent	T081	C0439165
27494908	1169	1176	class I	T185	C1550329
27494908	1191	1203	over-treated	T058	C4046039
27494908	1227	1238	intravenous	T169	C1522726
27494908	1239	1249	antibiotic	T195	C0003232
27494908	1257	1269	oral therapy	T061	C0559681
27494908	1310	1336	broad-spectrum antibiotics	T195	C0003232
27494908	1367	1375	class II	T185	C1550329
27494908	1381	1393	over-treated	T058	C4046039
27494908	1422	1448	broad-spectrum antibiotics	T195	C0003232
27494908	1458	1474	clinical failure	T033	C3640841
27494908	1522	1530	patients	T101	C0030705
27494908	1557	1565	response	T201	C0521982
27494908	1569	1577	class II	T185	C1550329
27494908	1579	1588	class III	T185	C1550329
27494908	1593	1601	class IV	T185	C1550329
27494908	1603	1616	Retrospective	T080	C1514923
27494908	1617	1628	application	T058	C0185125
27494908	1632	1637	CREST	T170	C0162791
27494908	1678	1688	management	T058	C0376636
27494908	1692	1697	SSTIs	T047	C0852000
27494908	1699	1704	CREST	T170	C0162791
27494908	1751	1757	severe	T080	C0205082
27494908	1758	1763	SSTIs	T047	C0852000
27494908	1778	1785	treated	T061	C0087111
27494908	1792	1802	outpatient	T101	C0029921